Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Imatinib . mesylate

Tyrosine kinase inhibitor
 
ALX-270-492-M025 25 mg 41.00 USD
 
ALX-270-492-M100 100 mg 109.00 USD
 
ALX-270-492-M500 500 mg 387.00 USD
Do you need bulk/larger quantities?
 
Tyrosine kinase inhibitor. Highly specific for BCR-ABL, the enzyme associated with chronic myelogenous leukemia (CML) and certain forms of acute lymphoblastic leukemia (ALL). Also shown to inhibit the transmembrane receptor kit and platelet-derived growth factor (PDGF) receptors.

Product Specification

Alternative Name:STI-571, CGP-57148B
 
Formula:C29H31N7O . CH3SO3H
 
MW:493.6 . 96.1
 
CAS:220127-57-1
 
MI:14: 4902
 
Purity:≥98% (HPLC)
 
Appearance:White to pale yellow crystalline powder.
 
Solubility:Soluble in water (200mg/ml) or DMSO (100mg/ml) or DMF (10mg/ml) or PBS (2mg/ml). Sparingly soluble in ethanol (0.2mg/ml). Storing aqueous solutions for more than one day is not recommended.
 
Shipping:Ambient
 
Long Term Storage:+4°C
 
270-492
Please mouse over
270-492

Product Literature References

Importance of pulmonary vein preferential fibrosis for atrial fibrillation promotion in hypertensive rat hearts: Y. Iwasaki, et al.; Can. J. Cardiol. 32, 767 (2016), Application(s): Cell Culture, Abstract;
Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling: M.T. Weigel, et al.; Cancer Lett. 273, 70 (2009), Abstract;
Imatinib as a novel therapeutic approach for fibrotic disorders: J.H. Distler & O. Distler; Rheumatology (Oxford) 48, 2 (2009), Abstract;
Imatinib mesylate for the treatment of chronic myeloid leukemia: S. Soverini, et al.; Expert Rev. Anticancer Ther. 8, 853 (2008), (Review), Abstract;
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?: F. Miselli, et al.; Transl. Oncol. 1, 177 (2008), Abstract;
Imatinib: C.E. de Kogel & J.H. Schellens; Oncologist 12, 1390 (2007), (Review), Abstract;
The kinase inhibitor imatinib--an immunosuppressive drug?: D. Wolf, et al.; Cancer Drug Targets 7, 251 (2007), (Review), Abstract;
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors: E. Buchdunger, et al.; J. Pharmacol. Exp. Ther. 295, 139 (2000), Abstract;
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative: E. Buchdunger, et al.; Cancer Res. 56, 100 (1996), Abstract;

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
Abl
PDGF receptor
By biological activity:
Abl Inhibitor
PDGF receptor Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,